Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

India is on the brink of a significant medical innovation with the upcoming launch of <keyword id="23029757" type="General" weightage="20" keywordseo="PresVu-eye-drops" source="keywords">PresVu eye drops</keyword>, a groundbreaking treatment aimed at reducing dependency on <keyword id="23034012" type="General" weightage="20" keywordseo="reading-glasses" source="keywords">reading glasses</keyword>. Developed by Mumbai-based <keyword id="20007796" type="General" weightage="20" keywordseo="Entod-Pharmaceuticals" source="keywords" meta.keywordsubtype="org" meta.entityname="Entod Pharmaceuticals" meta.hostid="261" meta.entityid="Entod Pharmaceuticals">Entod Pharmaceuticals</keyword>, PresVu has recently received approval from the Drug Controller General of India (DCGI) and is scheduled to hit the market in early October 2024. <h3 style="line-height:1.2;margin-top:14pt;margin-bottom:4pt;">What is PresVu?</h3>PresVu eye drops are designed to treat <keyword id="23035383" type="General" weightage="20" keywordseo="presbyopia" source="keywords">presbyopia</keyword>, a common age-related condition that affects the eye's ability to focus on nearby objects. This condition, which typically begins in the early 40s, leads to a gradual decline in <keyword id="23035385" type="General" weightage="20" keywordseo="near-vision" source="keywords">near vision</keyword>, making reading glasses a necessity for millions. As per estimates, nearly one third of Indian adults suffer from the condition. PresVu offers a novel solution, aiming to restore visual independence to those suffering from mild to moderate presbyopia. <div type="Article" hostid="261" msid="112800837" title="Scientists want to help drug addicts recover — by giving them psychedelics" mstype="2" mssubtype="0"></div><h2>How does it work?</h2>The drug contains <keyword id="23035386" type="General" weightage="20" keywordseo="pilocarpine-hydrochloride" source="keywords">pilocarpine hydrochloride</keyword> — a plant-derived compound that has been used for decades to treat various eye conditions and dry mouth. The drops are intended for daily use, with effects lasting several hours, allowing users to perform tasks like reading without the need for glasses. As per the company, the effects of the drops will be apparent within 15 minutes, but complete benefits are only apparent after 15 days of use. The treatment has been thoroughly tested in clinical trials across India and has shown promising results in improving near vision. <div type="Article" hostid="261" msid="112738885" title="India bans 156 commonly used combination drugs citing possible risks to humans" mstype="2" mssubtype="0"></div><h2>Market impact and accessibility</h2>The introduction of PresVu is expected to make a significant impact in India, where the prevalence of presbyopia is rising. As per media sources, each vial will be priced at Rs 345, making it an affordable alternative to reading glasses. Each vial is designed to last about a month, making it a cost-effective solution for long-term use. Entod Pharmaceuticals has ambitious plans for PresVu, targeting not just the Indian market but also emerging markets in Africa and Southeast Asia. The company sees this as a step towards becoming a global innovator in ophthalmology, with future plans to out-licence products in the US market. (Editor's note: PresVu eye-drops have since been suspended by the DCGI for making exaggerated marketing claims related to the product)

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

Mumbai, Jan 29 () Domestic pharma companies have the potential to grow their revenue from the US by almost five times at around USD 30 billion from USD 6.5 billion in 2018 if they properly tap just 10 of the widely consumed drugs in the world's largest drug market, according to an analysis by the World Trade Centre. Despite being the largest export market for domestic pharma makers, they served only a miniscule 5.6 per cent or USD 6.5 billion of the over USD 116 billion American pharma imports of in 2018, show the <keyword id="8679401" type="UNKNOWN" weightage="20" keywordseo="WTC-data">WTC data</keyword>. Despite having good demand from across the markets, primarily due to lower prices and easy availability, India controls only 2.4 per cent of global pharma exports. 
 With robust manufacturing capabilities, domestic pharma companies have the potential to enhance their exports to the US by almost five times to USD 29.6 billion, says the WTC in a note quoting data from the UN's International Trade Commission.
 The WTC has identified 10 products that constitute about 25 per cent of American pharma imports in 2018 at USD 29.6 billion which constitute about 17 per cent of US imports from India.
 These ten products include single vitamins, medicaments affecting central nervous system, cough &amp; cold preparations, dermatological agents &amp; local anesthetics, chemical contraceptives, sterile surgical catgut, antineoplastic &amp; immunosupressive medicaments, and structural analogues among others.
 These 10 products constitute around 25 per cent of American drug imports and but the share of Indian companies in 2018 was only worth USD 1 billion. 
 Domestic pharma companies shipped products worth USD 6.53 billion in 2018 to the US, which was only 5.61 per cent of total American imports worth USD 116.35 billion, showed WTC data. BEN MR
MR

Just ten drugs can add $30 billion to Indian pharma's US revenue, says a report

The entire list and a brief profile of 'Delhi ke nirmata'⁠— the makers of Delhi felicitated at Kejriwal's oath taking ceremony

<ul><li>As per World Health Organization estimates, India has around one-fifth of the global <keyword id="14208580" type="General" weightage="20" keywordseo="cervical-cancer-cases" source="Orion">cervical cancer cases</keyword>, with 1.23 lakh per annum and 67,000 fatalities.</li><li>Doctors and experts say that the only way to prevent <keyword id="28838" type="General" weightage="20" keywordseo="cervical-cancer" source="Orion">cervical cancer</keyword> is to administer the vaccine to young girls aged between 9 to 14 years before they get exposed to sexual activities.</li><li>Vaccines have proved to be 99% effective in preventing cancer from HPV.</li></ul>A fifth of the world’s cervical cancer cases are from India – adding 1.23 lakh new cases per annum. And as many as <a href="https://www.ndtv.com/health/cervical-cancer-as-the-vaccine-launches-against-cc-lets-understand-the-causes-and-risks-3310816">67,000 succumb</a> to the disease every year. In 2019, the number of fatalities caused by this deadly cancer was at 4 lakh, according to a report by World Health Organization (WHO). Doctors say that a good way to prevent cervical cancer is to administer a vaccine. “Large scientific studies have shown that HPV vaccines can prevent cervical cancer and death from cervical cancer. Cervical cancer affects women in their reproductive age group between 35-50 years and also after menopause,” Dr. Richa Bansal, gynec onco-surgery, Apollo Cancer Centres, Navi Mumbai told Business Insider. The vaccines however are best effective when administered before sexual intercourse. So doctors peg the right age at 9-14 years before sexual intercourse. Cervical cancer develops in the cells of the cervix — the lowermost part of the uterus in women, caused by <keyword id="58575" type="General" weightage="20" keywordseo="human-papillomavirus" source="Orion">human papillomavirus</keyword> (HPV), which is sexually transmitted. Doctors hope that a homegrown vaccine with cost benefits can have a major effect on the incidence and fatality of this cancer. <cmsannotation type="cmsannotation" annotationid="A Made-in-India vaccine" comment="subhead" text="A Made-in-India vaccine">A Made-in-India vaccine</cmsannotation> There are currently two vaccines available in the Indian market for cervical cancer — Merck’s quadrivalent vaccine Gardasil and GSK’s bivalent vaccine Cervarix. Gardasil costs around ₹2,800 per dose, while the bivalent vaccine costs ₹3,299 per dose. India will soon get its third vaccine from the <keyword id="95879" type="General" weightage="20" keywordseo="Serum-Institute-of-India" source="Orion">Serum Institute of India</keyword>, named Cervavac. The vaccine will be available in the market in the next few months, the central government announced on September 1. Cervavac is said to be effective against at least four variants of HPV and will be available at a price of around ₹200-₹400. That’s less than a tenth of what the current vaccines cost. “The newer ones (Cervavac) will be much cheaper and affordable for the people. The importance of a cheaper vaccine is to make it more accessible to a lot of people and prevent many patients from getting cervical cancer,” Dr. Sandeep Nayak P, director — department of surgical oncology and robotic and laparoscopic surgery, Fortis Hospitals, Bengaluru told Business Insider India. The production of the Cervavac vaccine will start in December or early next year. The Drugs Controller General of India (DGCI) granted the market authorisation to Serum Institute to manufacture the vaccine in July this year. Serum Insitute’s vaccine is expected to cover 90% of the population against HPV. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Vaccine </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cost per dose </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cervavac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹200-400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Gardasil </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2,800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cervarix </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹3,299 </td></tr></tbody></table>Source: Reports <cmsannotation type="cmsannotation" annotationid="Not just cervical cancer" comment="subhead" text="Not just cervical cancer">Not just cervical cancer</cmsannotation> In addition to showing 99% efficacy against cervical cancer, all the above vaccines are effective against other cancers too. Dr Nayak added that cervical cancer vaccines can also help prevent pharyngeal cancer, also caused by HPV. It’s also known to be effective against penile cancer in men. “This persistent infection in the cervix can lead to malignant changes in the cells of the cervix. The abnormal cells on the surface of the cervix, can extend deeper and travel to other parts of the body. This risk of developing cervical cancer can be reduced through vaccination against HPV. The trials have proved that there is 99% effectiveness of HPV vaccine in preventing cancer from HPV 16 and 18,” said Dr. Sarika Gupta, senior consultant, oncology and robotic gynecology, Indraprastha Apollo Hospital, New Delhi. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/lenskart-and-mirae-asset-capital-sign-up-with-razorpay-for-online-transactions/articleshow/94150744.cms">Lenskart and Mirae Asset Capital sign up with Razorpay for online transactions</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/quirky-maker-of-flip-flops-merges-style-with-sustainability/articleshow/94145373.cms">Quirky maker of flip flops merges style with sustainability</a>

India’s homegrown cervical cancer vaccine can be a game changer say doctors

<ul><li>Today is the first day to subscribe to the <keyword id="11265715" type="General" weightage="20" keywordseo="supriya-lifescience-ipo" source="Orion">Supriya Lifescience IPO</keyword>, which will close on December 20.</li><li>The pharmaceutical company is intending to raise ₹700 crore through the IPO, which consists of a fresh issue of ₹200 crore and offer for sale of ₹500 crore.</li><li>Shares of the company are demanding a premium of ₹250 per share in the grey market .</li><li>Analysts recommend subscribing to the issue on some positive factors — diversified product portfolio, strong foothold in international markets, valuation at a discount compared to peers.</li></ul>Amid myriad initial public offerings (IPO) going on, here is another one worth giving attention to, as analysts recommend subscribing to this one on its good fundamentals. Today is the first day to subscribe to the initial public offering (IPO) of Mumbai-based active pharmaceutical ingredients (APIs) manufacturer, Supriya Lifescience. The company produces 38 active pharmaceutical ingredients (APIs) focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company’s manufacturing facility is in Parshuram Lote, about 250 kilometres away from Mumbai, Maharashtra. Supriya Lifescience is looking to raise ₹700 crore through the IPO, which consists of a fresh issue of ₹200 crore and an offer for sale of ₹500 crore. Most analysts are positive and suggest subscribing to the issue because of its diversified product range, strong foothold in international markets and valuation at discount compared to peers. Adding to it, shares of the company are demanding a premium of ₹250 per share in the grey market . <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brokerages </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Angel One </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Choice Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">BP Equities </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investmentz </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Religare Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Positive view on a long term </td></tr></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody></table> Supriya Lifescience’s products have been exported to 86 countries and 1,296 customers in FY21. The company has API business in Europe, Latin America, Asia, and North America. Its products are registered with various international regulatory authorities including the US, Europe and China. “Supriya Lifescience has de-risked its business model with wide geographical presence, diversified product portfolio, catering to diverse therapeutic areas. Also the company has demonstrated a healthy profitable business growth with stable operating cash flows. Since inception, it has reported a positive operating cash flow,” said analysts at Choice Broking while assigning a “SUBSCRIBE” rating for the issue given the valuation is at discount to the peer average. Analysts from stock broking firm Investmentz say that with the company’s superior product mix, established brand name, strong relationships with leading global companies, and adding capacities, “we believe the company is well placed to capitalise on domestic and global opportunities”. Considering the company’s niche product portfolio and strong geographical presence, its valuation seems attractive to analysts. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Peer company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revenue for FY21 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stock price </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">% returns in 2021 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Solara Active Pharma Sciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,645 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,088 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-7.9% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Neuland Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹953 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,591 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">45% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Aarti Drugs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2,159 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹984 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-24% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Wanbury </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹394.9 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹83 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">77% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Divi’s Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹7,032 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4,586 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Supriya Lifescience </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹396 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹265 - ₹274 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">- </td></tr></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody></table> “Supriya Lifescience focuses on research and development and having a diversified niche product portfolio of API’s. Companies 77.5% of revenue comes from the Export market, companies’ key markets are USA, Europe, China and India. We believe that the company's new manufacturing unit and product launch will be growth drivers for the company in future,” said a report by Angel One. The issue is attractively priced at the upper end of the price band, which is significantly discounted to its listed peers with similar return and margin profile explained a report by BP Equities. <div type="image" title="supriya life rev 2" height="900" width="1200" msid="88314031" hostid="261"></div> SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/retail/news/aditya-birla-fashion-will-now-sell-reebok-products-in-india-and-10-other-asian-countries/articleshow/88272443.cms">Aditya Birla Fashion will now sell Reebok products in 11 Asian countries — and it may reap benefits soon</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/moschip-technologies-asm-technologies-and-spel-semiconductor-among-chip-makers-stock-that-surged-on-pli-scheme/articleshow/88306809.cms">Checkout chip makers’ stocks that surged on PLI scheme; industry leaders feel the move will make India self-reliant</a>

Analysts suggest subscribing to this pharma company IPO on discounted valuation and strong product portfolio than peers

<ul><li>The 30-share BSE index was trading 0.87% higher; while NSE Nifty jumped 96.05 points at 9:50 am </li><li>These were the top losers and gainers in the Nifty pack. </li><li>These are the top stocks that are buzzing in trade today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock market index Sensex jumped over 300 points in early trade on Monday, tracking gains in index majors ICICI Bank, HDFC Bank and Reliance Industries amid positive trend in Asian markets. The 30-share BSE index was trading 0.87% higher; while NSE Nifty jumped 96.05 points at 9:50 am These were the top losers and gainers in the Nifty pack: <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Gainers </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Losers </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">ONGC </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TCS </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Bajaj Finance </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Infosys </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Adani Ports </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tata Motors </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Bharti Infratel </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Coal India </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HUL </td></tr></tbody></table>*as of September 24, 10:00 am These are the top stocks in news today. Future Group stocks The shares of Future Group companies rallied after media <a href="https://www.thehindubusinessline.com/money-and-banking/biyani-close-to-deal-with-sbi-to-future-proof-insurance-arms/article32709290.ece">reports </a>claimed that as a part of a plan to cut down on debt, the Kishore Biyani-owned Future Group is set to ink a deal with State Bank of India for the sale of both the general and life insurance segments. At 9:50 am, Future Enterprises Future Lifestyle, Future Retail were locked in a 5% upper circuit set by the stock-exchanges. Hero MotoCorp rallied 2% The shares of Indian bike major Hero MotoCorp gained 2% after <a href="https://www.timesnownews.com/business-economy/companies/article/harley-davidson-close-to-deal-with-indias-hero-motocorp-after-stopping-local-manufacturing-sources/657938">media reports</a> surfaced that the US bike maker Harley Davidson is in talks with the Indian two-wheeler major to enter into a distribution arrangement. This will allow the Indian company to import and sell Harley bikes as its sole distributor. Indoco Remedies gain 5% The Mumbai based drug maker Indoco Remedies launched its own version of generic Favipiravir under the brand name Fevindo. The drug approved by DCGI in the treatment of Covid-19, Fevindo-400 is an antiviral drug, effective against the RNA‐based influenza virus. Vodafone Idea up 4% The shares of Vodafone Idea surged 4% during the early trade hours on Monday. This after the telecom regulator TRAI, decided to drop proceedings against Vodafone Idea in priority plan matter after the telco withdrew contentious claims on faster speed and modified its offering. Surya Roshni leaps 7% The shares of Indian multinational company Surya Roshni surged 7% after bagging ₹272.86 crore order for the supply of Coated API Line Pipes to GAIL (India) and Indradhanush Gas Grid (IGGL) for the North-East Gas Grid PipeLine project. PVR Limited up 7% PVR Limited shares surged during the early trade hours on Monday after Mamata Banerjee led West Bengal government has allowed the reopening of cinema halls from October 1 with certain Covid-19 restrictions. NTPC up 4% The shares of NTPC surged 4% after the state-owned company said it has successfully synchronized a 660-MW unit of its supercritical thermal power plant in Bihar with the grid. SEE ALSO: <a href="https://www.businessinsider.in/india/news/hyperloop-in-bengaluru-might-help-you-reach-the-city-in-10-minutes-from-the-airport/articleshow/78357354.cms" data-type="tilCustomLink">Hyperloop in Bengaluru might help you reach the city in 10 minutes from the airport</a> <a href="https://www.businessinsider.in/thelife/news/the-10-richest-family-aposdynastiesapos-in-asia-who-have-a-collective-net-worth-of-over-250-billion/10-the-kwek/slidelist/78298350.cms" data-type="tilCustomLink">The 10 richest family 'dynasties' in Asia, who have a collective net worth of over $250 billion</a>

Top stock movers — Future Retail, Hero MotoCorp, Indoco Remedies, Surya Roshni, PVR, Vodafone-Idea and more

New Delhi, Nov 22 () Drug maker Lupin on Friday said it has launched a device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.
 The device -- Adhero -- would help the patients track their MDI usage and facilitate improved adherence to therapy, Lupin Ltd said in a statement.
 The bluetooth-enabled device is attached to the top of a MDI and with built-in sensors helps track a patient's daily medication usage and consumption pattern.
 The inhalers are the preferred treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) in the country.
 However, it is estimated that nearly 45 per cent patients do not adhere to therapy in terms of filling, refilling prescriptions or maintaining prescribed medication schedule, which adversely impacts clinical outcomes.
 The Mumbai-based drug maker said it has collaborated with Aptar Pharma, a leading provider of drug-delivery devices, components and services in bringing the device to the market.
 "The launch of Adhero will be of great help to patients using metered-dose inhalers as well as for doctors to track adherence and compliance to therapy, thereby improving clinical outcomes and quality of life of patients," Lupin President (India Region Formulations) Rajeev Sibal said.
 Last year, Lupin had launched Anya, an artificial intelligence-powered health chatbot hosted on Facebook Messenger to raise health awareness and help patients get medically verified responses to their disease and treatment-related queries.
 Originally configured to respond to diabetes and tuberculosis-related queries, Anya now features enhanced capabilities of answering queries on respiratory ailments such as COPD and Asthma.
 Shares of the company were trading 0.05 per cent up at Rs 771.10 apiece on the BSE. MSS HRS

Lupin launches device to track metered-dose inhaler usage pattern in patients

Chinese vaccine maker <keyword id="9550548" type="PERSON" weightage="20" keywordseo="anhui-zhifei-longcom-biopharmaceutical">Anhui Zhifei Longcom Biopharmaceutical</keyword> Co., Ltd. has commenced the phase-3 clinical trials for its Covid-19 vaccine, planning to recruit 29,000 volunteers across the world. This is China's first phase-3 efficacy study for a recombinant subunit COVID-19 vaccine candidate, the company said in a statement on Thursday. Jointly developed by the company and the Institute of Microbiology under the Chinese Academy of Sciences, the vaccine was issued with a clinical research permit from the National Medical Products Administration on June 19, reports Xinhua news agency. Researchers started phase-1 and phase-2 clinical trials on June 23, which were randomized, double-blind and placebo-controlled. Volunteers, aged between 18 and 59 from Beijing, Chongqing and Hunan, received the vaccine to determine whether it is safe for use on humans. The results of the early-stage trials support the safety and immunogenicity of this vaccine, suggesting the potential for further clinical tests. The Chinese drug regulator granted the developers permission to conduct global multi-centre research on November 4. The company said the research, which plans to enroll up to 29,000 adults aged 18 and up, was launched on Wednesday in Xiangtan county, Hunan province. Global trials are expected to begin in Uzbekistan late this month, followed by trials in Indonesia, Pakistan and Ecuador. A Covid-19 vaccine manufacturing plant of the company was put into use in September. The annual production capacity for the Covid-19 vaccine will top 300 million doses, according to the company. A Foreign Ministry spokesperson said on Wednesday that China had five Covid-19 vaccine candidates undergoing phase-3 trials in the United Arab Emirates, Brazil, Pakistan and Peru. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/mumbais-massive-power-cut-last-month-may-have-been-the-work-of-hackers/articleshow/79318282.cms">Mumbai’s massive power cut last month may have been the work of hackers</a> <a href="https://www.businessinsider.in/stock-market/news/vodafone-idea-shares-jump-after-selling-stake-in-indus-towers-for-3760-crore/articleshow/79316662.cms">Vodafone Idea soars nearly 5% on fund infusion from Indus Towers stake sale</a> <a href="https://www.businessinsider.in/tech/apps/news/pubg-mobile-india-was-supposed-to-launch-today/articleshow/79315462.cms">PUBG Mobile India was rumoured to launch today — but there is no official update from the company</a>

Another Chinese Covid-19 vaccine enters late-stage human trials with a plan to produce 300 million doses annually

New Delhi, Dec 18 () Drug maker Lupin on Tuesday said its subsidiary Nanomi BV has completed divestment of its entire stake in Kyowa Pharmaceutical Industry to Japan-based equity fund Unison Capital Partners.
Nanomi BV held 99.82 per cent stake in Japan-based Kyowa, Lupin said in a statement. 
 Last month, Lupin's board had approved the stake sale in Kyowa for an enterprise value of JPY 57,361 million (around Rs 3,702 crore).
The Mumbai-based drug firm said the transaction generates post tax net cash inflow of around JPY 33,429 million (Rs 2,157.6 crore) and significantly strengthens its consolidated balance sheet.
The deal helps the company pare its net debt from Rs 4,361.8 crore (as on September 30, 2019) to Rs 1,075.3 crore.
The company's net debt to equity ratio now stands at 0.08 as compared to 0.32 earlier.
 "This transaction enables us to strengthen our balance sheet and unlock significant value for the company and is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth," Lupin Managing Director Nilesh Gupta said.
 The company would continue to selectively monetise its complex generics, biosimilars and specialty assets in Japan with the right partners, including Unison, he added.
Lupin shares were trading 0.87 per cent up at Rs 754 apiece on the BSE. MSS ANU

Lupin's arm completes stake divestment in Kyowa

Mumbai, Mar 24 () Led by market leader Diageo, the liquor industry is joining hands with state governments to fight the coronavirus pandemic by manufacturing and supplying hand sanitisers. The coronavirus pandemic has led to a high demand for sanitisers as hand washing is an effective way to keep the infection away. Liquor companies like Diageo and Radico Khaitan have decided to stop bottling alcohol at some of their plants and instead make hand sanitisers following an appeal by the government and a promise to give them the needed permits. "We will support the government and the hospitality sector during this pandemic by manufacturing 3 lakh litres of bulk hand sanitisers from our 15 units across the country," Anand Kripalu, managing director and chief executive officer of Diageo India, said. As part of the initiative, the company will also donate 5 lakh litres of ENA (Extra Neutral Alcohol), which is a key ingredient in making sanitisers, to the sanitiser industry, he said in a statement. This amount of ENA can produce more than 2 million units (250 ml each) of hand sanitisers, he added. Diageo is the country's largest liquor maker. The country's second largest liquor maker Allied Blenders &amp; Distillers, which produces the globally largest selling whiskey Officer's Choice, said it has not decided on manufacturing hand sanitisers since there is a tedious licensing process. "We have not taken a final call on this. A liquor company cannot make something that needs a drug licence under the existing licence. Having said so, it does not mean we will not do our bit to help the nation," Deepak Roy, vice-chairman of ABD, told over phone on Tuesday. Smaller player Radico Khaitan said it would start producing sanitisers from its Rampur distillery and has already applied for necessary permissions. It has also chalked out distribution plans. "Being a leading spirit manufacturer, we have decided to extend our support to the country in this worrisome time of the coronavirus outbreak," Radico Khaitan Chief Operating Officer Amar Sinha said in a statement. "Radico Khaitan has kick-started expanding the use of ENA at its mother distillery in Rampur into production of hand sanitiser which will be available at retail stores in a few days," he added. According to Kripalu, Diageo has also announced health insurance cover to on-trade partners and donation of free masks to government public health departments. As part of this initiative, it is offering health insurance cover worth Rs 3 crore to bartenders and would also donate around 1,50,000 masks to the public health departments of five states. An e-mail sent to the All India Distillers Association did not elicit a response on questions about other distillers' efforts towards making hand sanitisers. Last week, FMCG leader HUL cut the prices of its handwash product and also promised to increase production to help alleviate supplies issues in the wake of the coronavirus pandemic. Beauty products maker VLCC has also started production of hand sanitisers. Some liquor companies overseas are also in the process of making hand sanitisers. "While we advise that you cannot use our standard vodka product as a hand sanitizer, our team at the distillery has been working hard to get all of the pieces in place to begin production on a hand sanitizer that adheres to industry and governmental guidance," American vodka maker Tito's said in a tweet on Sunday. BEN RAM HRS

Coronavirus: Liquor majors Diageo, Radico to make hand sanitisers now

<ul><li>At 7:45 am, the SGX Nifty was up 1.12%, indicating a green start for Nifty50.</li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider. </a><a href="https://www.businessinsider.in/"></a></li></ul>Indian stock-market indices are likely to start higher on Monday, led by positive cues from the Asian markets. Most global markets were shut on January 1 and began trading for the first time in 2021. At 7:45 am, the SGX Nifty was up 1.12%, indicating a green start for Nifty50. Other Asian peers were trading in the positive territory as well — the SSE Composite Index was up 0.19%, and the Hang Seng Index was up 0.54%. These are the <keyword id="1044313" type="PERSON" weightage="20" keywordseo="Stocks-to-watch-out-for">stocks to watch out for</keyword> during the trading session today: RIL Market regulator <a href="https://www.businessinsider.in/business/news/sebi-imposes-penalty-on-mukesh-ambani-and-reliance-industries-for-manipulative-trading/articleshow/80071715.cms" data-type="tilCustomLink">SEBI has imposed penalties on Reliance Industries</a> chairman Mukesh Ambani as well as two other entities for alleged manipulative trading in the shares of erstwhile Reliance Petroleum (RPL) back in November 2007. Fines of ₹25 crore and ₹15 crore have been imposed on Reliance Industries (RIL) and Ambani, respectively. Besides, Navi Mumbai SEZ Pvt Ltd has been asked to pay a penalty of ₹20 crore, and Mumbai SEZ has been directed to pay ₹10 crore. <keyword id="6398500" type="ORGANIZATION" weightage="20" keywordseo="beml">BEML</keyword> On Sunday, the government invited preliminary bids for strategic sale of 26% stake and transfer of management control in defence PSU BEML. A 26% sale could fetch about ₹1,000 crore to the exchequer at the current market price. Rashtriya Chemicals &amp; Fertilisers The government plans to sell a 10% stake in Rashtriya Chemical and Fertilizers (RCFL) and invited bids from merchant bankers and legal firms to manage the share sale process. The government holds a 75% stake in RCFL and intends to disinvest 10% of the paid-up equity capital through an offer for sale (OFS). HCL Tech, <keyword id="6354512" type="COMPANY" weightage="20" keywordseo="Infosys">Infosys</keyword>, <keyword id="43217" type="CITY" weightage="20" keywordseo="Tech-Mahindra">Tech Mahindra</keyword>, TCS and other IT stocks HCL Tech, Infosys, Tech Mahindra, TCS, and other IT stocks will focus on trade today. <a href="https://www.business-standard.com/article/companies/trump-extends-freeze-on-h-1b-visas-green-cards-it-companies-to-take-hit-121010101134_1.html" data-type="tilCustomLink">US President Donald Trump has extended the freeze</a> on the most sought-after H-1B visas by Indian IT professionals, along with other types of foreign work visas and green cards through March 31 to protect American workers, saying that the reasons for which he had imposed such restrictions amidst the pandemic have not changed. Trump ordered the freeze on various categories of work visas through two proclamations on April 22 and June 22 last year. Tata Motors Tata Motors on Friday reported a 21% increase in total vehicle sales in the domestic market to 53,430 units in December. The company said its PV business has been witnessing the strong response to its 'New Forever' range, which is being supported by a continuous ramp-up of supplies. Hero MotoCorp On Friday, the country's largest two-wheeler maker Hero MotoCorp reported a 5.02% increase in total sales at 4,47,335 units in December. The company said it further consolidated its market leadership by clocking its best-ever third quarter, with 18.45 lakh units sold during the October-December period. <keyword id="62356" type="COMPANY" weightage="20" keywordseo="TVS">TVS</keyword> Motor Company TVS Motor reported a 17.5% increase in total sales to 2,72,084 units in December. The company said its total exports increased by 28% to 94,269 units last month, as against 73,512 in the year-ago period. Edelweiss Financial Services Edelweiss Financial Services (EFSL) has decided to close its public issue of secured redeemable non-convertible debentures (NCDs) on January 4 against the scheduled close of January 15. The company said its debenture fundraising committee decided to exercise early closure and close the issue on January 4. Adani Gas The name of Adani Gas has now changed to Adani Total Gas from January 1. Adani Total Gas is a joint venture company of Adani Group and Total of France. SEE ALSO: <a href="https://www.businessinsider.in/india/news/aidan-asks-dcgi-to-withdraw-approval-for-bharat-biotechs-covaxin/articleshow/80078041.cms">A drug activists' group says it is 'baffled' by the approval given to Bharat Biotech's Covaxin</a> <a href="https://www.businessinsider.in/business/auto/news/checkout-upcoming-new-cars-in-year-2021/slidelist/80025993.cms">Upcoming new cars in India in 2021 of Maruti, Tata, MG, Audi</a> <a href="https://www.businessinsider.in/stock-market/news/bitcoin-crosses-30000-for-the-first-time-as-it-charges-into-2021/articleshow/80078034.cms">Bitcoin crosses $30,000 for the first time as it charges into 2021</a>

You Searched For "Mumbai drug maker" and got 12 results

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

BI India Bureau

Just ten drugs can add $30 billion to Indian pharma's US revenue, says a report

PTI

The entire list and a brief profile of 'Delhi ke nirmata'⁠— the makers of Delhi felicitated at Kejriwal's oath taking ceremony

BI India Bureau

India’s homegrown cervical cancer vaccine can be a game changer say doctors

Vaamanaa Sethi

Analysts suggest subscribing to this pharma company IPO on discounted valuation and strong product portfolio than peers

Bhakti Makwana

Top stock movers — Future Retail, Hero MotoCorp, Indoco Remedies, Surya Roshni, PVR, Vodafone-Idea and more

Navdeep Yadav

Lupin launches device to track metered-dose inhaler usage pattern in patients

PTI

Another Chinese Covid-19 vaccine enters late-stage human trials with a plan to produce 300 million doses annually

IANS

Lupin's arm completes stake divestment in Kyowa

PTI

Coronavirus: Liquor majors Diageo, Radico to make hand sanitisers now

PTI

Top stocks to watch — BEML, HCL Tech, Infosys, Tech Mahindra, TCS, RIL, Tata Motors Hero Moto, TVS, and others

Navdeep Yadav

From Adani Group to Tata Motors and banks ⁠— these 17 stocks have already lost over 10% in last one month

Bhakti Makwana

Popular Keywords

Buying Guides